How low can you get?

Annals of the New York Academy of Sciences

Volumn 997, Issue , 2003, Pages 158-162

  Brincat, M ^a   Muscat Baron, Y ^a   Galea, R ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Birth control; Estrogin; Gesogen; Oral contraceptives; Progestin

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT; STEROID;

AMENORRHEA; BIRTH CONTROL; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOMETRIUM; ESTROGEN RELEASE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; LOW DRUG DOSE; MASTALGIA; MENORRHAGIA; METRORRHAGIA; MIGRAINE; NAUSEA; PATIENT COMPLIANCE; PATIENT SATISFACTION; SIDE EFFECT; SPOTTING; VASCULAR DISEASE; VOMITING; WEIGHT GAIN; ADULT; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; MENSTRUAL CYCLE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHINYL ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; MULTICENTER STUDIES; PROGESTINS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 1842841578     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1290.018     Document Type: Conference Paper

References (14)

1. VANDENBROUCKE, J.P. 2001. From pill to pill: oral contraception, venous thrombosis and coagulation disorders. Verh. K. Acad. Geneeskd. Belg. 63: 243-252.
2. MIDDELDORP, S., J. ROSING & H.R. BOUMEN BULLEN. 2001. Effects of second and third generation oral contraceptives on haemostasis. New Tijdischr. Geneeskd. 145: 252-256.
3. DARNEY, P.D. 1997. OC practice guidelines: minimising side effects. Int. J. Fertil. Women Med. 1: 158-169.
4. OAKELY, L., M.Y. Yu, X.C. ZHANG, et al. 1999. Combining qualitative with quantitative approaches to study contraceptive pill use. 2: 249-257.
5. BROOKS, T.C. & L.A. SHRIER. 1999. An update on contraception for adolescents. Adolesc. Med. 10: 211-219.
6. APGAR, B.S. & G. GREENBERG. 2000. Using progesterone in clinical practice. Am. Fam. Physician 62: 1839-1846.
7. VAN VLIET, H., D. GRIMES, F. HELMERHOST & W. SHULZ. 2001. Biphasic versus monophasic oral contraceptive for contraception. Cochrane Database. Syst. Rev. (2) CD 002032.
8. ROSENBERG, M.J. & S.C. LONG. 1992. Oral contraceptive and cycle control: a critical review of the literature. Adv. Contracept. Suppl. 1: 35-45.
9. DUSTERBERG, B., H. ELLMEN, U. MULLEN, et al. 1996. A three-year clinical investigation of efficacy, cycle control, and tolerability of a new low dose monophasic oral contraceptive containing gestodene. Gynecol. Endocrinol. 10: 33-39.
10. REES, M.C., M.K. OEHLER & R. BICKNELL. 2000. Steroids and the endometrium. Curr. Med. Chem. 7: 543-560.
11. GESTODENE STUDY GROUP. 1999. Eur. J. Contra Reprod. Health Care.
12. COLLI, E., D. TONG, R. PENHALLEGON & F. PARAZZINI. 1999. Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand. Contraception 59: 227-231.
13. MINESSE REGISTRATION FILE.
14. SULLIVAN, H., H. FURNISS, J. SPONE & M. ELSTEIN. 1999. Effects of 21-day and 24-day oral contraceptive regiment containing gestodene (60 microg/and ethyl estradiol (15 microg) on ovarian activity. Fertil. Steril. 72: 115-120.